Acumen Pharmaceuticals Inc. reported a net loss of $26.5 million for the third quarter of 2025, compared to a net loss of $29.8 million for the same period in 2024. Cash, cash equivalents, and marketable securities totaled $136.1 million as of September 30, 2025, down from $166.2 million as of June 30, 2025. The company expects its cash position to support current clinical and operational activities into early 2027. Key business developments include the anticipated decision on advancing an amyloid beta oligomer-targeted Enhanced Brain Delivery product candidate in early 2026, and expected topline results from the Phase 2 ALTITUDE-AD study investigating sabirnetug for early Alzheimer's disease in late 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573741-en) on November 12, 2025, and is solely responsible for the information contained therein.